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Over the last decade, striatal cholinergic interneurons (ChIs) have reemerged as key actors in the pathophysiology of basal-ganglia-
related movement disorders. However, the mechanisms involved are still unclear. In this study, we address the role of ChI activity in the
expression of parkinsonian-like motor deficits in a unilateral nigrostriatal 6-hydroxydopamine (6-OHDA) lesion model using optoge-
netic and pharmacological approaches. Dorsal striatal photoinhibition of ChIs in lesioned ChAT cre/cre mice expressing halorhodopsin in
ChIs reduces akinesia, bradykinesia, and sensorimotor neglect. Muscarinic acetylcholine receptor (mAChR) blockade by scopolamine
produces similar anti-parkinsonian effects. To decipher which of the mAChR subtypes provides these beneficial effects, systemic and
intrastriatal administration of the selective M1 and M4 mAChR antagonists telenzepine and tropicamide, respectively, were tested in the
same model of Parkinson’s disease. The two compounds alleviate 6-OHDA lesion-induced motor deficits. Telenzepine produces its
beneficial effects by blocking postsynaptic M1 mAChRs expressed on medium spiny neurons (MSNs) at the origin of the indirect
striatopallidal and direct striatonigral pathways. The anti-parkinsonian effects of tropicamide were almost completely abolished in
mutant lesioned mice that lack M4 mAChRs specifically in dopamine D1-receptor-expressing neurons, suggesting that postsynaptic M4
mAChRs expressed on direct MSNs mediate the antiakinetic action of tropicamide. The present results show that altered cholinergic transmis-
sion via M1 and M4 mAChRs of the dorsal striatum plays a pivotal role in the occurrence of motor symptoms in Parkinson’s disease.
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Introduction
Parkinson’s disease is the most common movement disorder and
is associated with akinesia, rigidity, and tremor but also cognitive
deficits (Obeso et al., 2000). Neuropathologically, it is defined by
a massive degeneration of nigrostriatal dopaminergic neurons.
Antimuscarinic drugs were the first widely accepted treatment
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Significance Statement
The striatum, where dopaminergic and cholinergic systems interact, is the pivotal structure of basal ganglia involved in patho-
physiological changes underlying Parkinson’s disease. Here, using optogenetic and pharmacological approaches, we investigated
the involvement of striatal cholinergic interneurons (ChIs) and muscarinic receptor subtypes (mAChRs) in the occurrence of a
wide range of motor deficits such as akinesia, bradykinesia, motor coordination, and sensorimotor neglect after unilateral nigro-
striatal 6-hydroxydopamine lesion in mice. Our results show that photoinhibition of ChIs in the dorsal striatum and pharmaco-
logical blockade of muscarinic receptors, specifically postsynaptic M1 and M4 mAChRs, alleviate lesion-induced motor deficits.
The present study points to these receptor subtypes as potential targets for the symptomatic treatment of parkinsonian-like motor
symptoms.
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before the discovery of 3,4-dyhydroxy-phenyl-L-alanine (L-
DOPA), the dopaminergic replacement therapy. They are mainly
prescribed to treat tremor (Lees, 2005) and hypertonia, but pro-
duce troublesome side effects, including urinary retention, nau-
sea, falls, and cognitive impairment. However, the discovery of
drugs acting on specific muscarinic acetylcholine receptor
(mAChR) subtypes has raised renewed interest in the modulation
of striatal cholinergic signaling to alleviate basal ganglia disorders
(Wess et al., 2007; Eskow Jaunarajs et al., 2015; Shen et al., 2015).
Increased excitability of the tonically active striatal cholinergic
interneurons (ChIs), which represent 1–2% of all striatal neu-
rons, may contribute to the dysregulated striatal output pathways
in the parkinsonian state because of their dense terminal fields
that are primarily directed to the medium spiny neurons (MSNs),
which constitute 95% of the striatal neuronal population (Tepper
and Bolam, 2004; Silberberg and Bolam, 2015). Current views of
basal ganglia dysfunction suggest that an imbalance between ace-
tylcholine (ACh) and dopamine (DA) activity in the striatum is
central to the development of motor symptoms (Di Chiara et al.,
1994; Pisani et al., 2007), although recent studies have demon-
strated complex and complementary interaction between these
two systems upon thalamic stimulation (Threlfell et al., 2012;
Parker et al., 2016). In addition, striatal dopaminergic depletion
produces profound alterations in the corticostriatal glutamater-
gic inputs and in GABAergic MSNs (Calabresi et al., 2000;
Surmeier et al., 2014; Tritsch and Carter, 2016). The DA D1-
receptor-expressing MSNs of the direct pathway (D1-MSNs),
which project directly to the substantia nigra pars reticulata
(SNr) output structure of the basal ganglia, become hypoactive,
whereas D2-receptor-expressing MSNs (D2-MSNs) of the indi-
rect pathway, which project to the globus pallidus and then the
subthalamic nucleus and the SNr, become functionally hyperac-
tive (Albin et al., 1989). This classical view of basal ganglia func-
tional organization has recently been challenged (Calabresi et al.,
2014; Tecuapetla et al., 2014).
ChIs have a wide range of striatal effects through both musca-
rinic and nicotinic receptors signaling. Muscarinic receptors
(mAChRs) are highly expressed within the striatum and primar-
ily on MSNs (Zhou et al., 2003; Kreitzer, 2009). Five distinct
G-protein-coupled mAChRs (M1–M5) have been cloned and di-
vided into two main classes according to their pharmacological
properties and transduction mechanisms (Wess et al., 2007). The
M1 class (M1, M3, and M5) is coupled to Gq/11, whereas the M2
-class (M2 and M4) is coupled to Gi/o proteins. Receptor local-
ization studies have revealed a predominant expression of M1
and M4 mAChRs within the striatum, whereas M2 and M3
mAChRs are clearly less abundant (Zhang et al., 2002; Zhou et al.,
2003; Pisani et al., 2007; Langmead et al., 2008; Bonsi et al., 2011)
Both types of MSNs possess postsynaptic M1 mAChRs, whereas
M4 mAChRs are preferentially expressed postsynaptically on D1-
MSNs. M4 mAChRs are also found presynaptically on ChIs,
where they mediate a negative feedback control on ACh release.
The rationale for blocking these receptors selectively in the par-
kinsonian state deserves to be investigated.
Defining the role of striatal ChIs on motor functions has re-
gained interest using techniques that allow selective ablation
of striatal ChIs by diphtheria toxin (Won et al., 2014) or
immunotoxin-mediated cell-targeting techniques (Kaneko et al.,
2000; Hikida et al., 2001). Optogenetic modulation of striatal
ChIs provides a potent way to decipher ChI functions in the
parkinsonian condition in a reversible manner. Here, we used a
mice model of Parkinson’s disease to investigate the role of ChIs
and M1 or M4 mAChRs in the control of motor function.
Materials and Methods
Animals
Optogenetics. Choline acetyltransferase (ChAT)-IRES-Cre knock-in
mice (ChAT cre/cre mice, stock number 006410, RRID:IMSR_JAX:
006410) were purchased from Jackson Laboratory.
Pharmacology. Wild-type male C57BL/6 mice (RRID:IMSR_JAX:
000664) 8 weeks of age were purchased from Charles River Laboratories.
D1-M4-KO mice were generated as described previously (Jeon et al.,
2010). Homozygous floxed M4 female mice were crossed with homozy-
gous floxed M4 male mice that carry the D1-Cre transgene. The resulting
mutant mice were then intermated to generate mutant mice that lacked
M4 mAChRs only in D1-receptor-expressing neurons (M4 fl/fl D1-Cre
mice; referred to as D1-M4-KO mice). This mating scheme also yielded
floxed M4 mAChRs mice lacking the D1-Cre transgene. These mice were
used as control animals throughout the experiments (M4 fl/fl mice; also
referred to as control littermates).
Mice were housed in groups of 4 –5 with food and water ad libitum in
a temperature-controlled room (24°C) on a 12:12 h dark/light cycle
(lights on at 07:00). All procedures were approved by the French National
Ethical Committee (authorization no. 00196.01) and in accordance with
the recommendations of the EEC (2010/63/UE) for the care and use of
laboratory animals.
Genotyping
Genotyping were performed by PCR analysis of mouse tail genomic DNA
using the following primers: forward, 5!-CCTGGAAAATGCTTCTG
TCCG-3! and reverse, 5!-CAGGGTGTTATAAGCAATCCC-3!. After an
activation step of 10 min at 94°C, the amplification reactions were performed
for 32 cycles of 30 s at 94°C, 30 s at 60°C, and 45 s at 72°C, followed by an
additional step at 72°C for 7 min. PCRs were run on an iCycler Thermal
Cycler apparatus (Bio-Rad) and PCR products were visualized by electro-
phoresis in 2% agarose gels. The amplicons were visualized with ethidium
bromide by digital scanning with the Bio-Vision image acquisition system
(Vilber-Lourmat).
Stereotaxic surgery
Mice were anesthetized with intraperitoneal injections of ketamine and
xylazine (100 and 10 mg/kg, respectively) and mounted on a stereotaxic
apparatus (Kopf Instruments). Injections were made with a 10 !l Ham-
ilton microsyringe connected to the injector (33 gauge; Plastics One) by
a polyethylene tubing (Tygon catheter; 0.25 mm internal diameter) and
controlled by an injection pump (CMA/100; CMA/Microdialysis) at the
flow of 0.3 !l/min. At the end of the injection, injector needles were left
in place for 3 more minutes to allow the diffusion of solutions.
Viral expression of opsins in ChIs. Adeno-associated virus (AAV) vector
containing opsin transgenes (eNpHR: pAAV-Ef1a-DIO-eNpHR3.0-
EYFP) was provided by Dr. Deisseroth (Stanford University) and modi-
fied by switching EYFP by TagRFP. The recombinant AAV vector was
serotyped with AAV5 coat proteins and packaged by the viral vector core
at the University of North Carolina. eNpHR-RFP or RFP was expressed
in ChAT-expressing neurons by injecting a Cre-dependent AAV carrying
the opsin (i.e., eNpHR-RFP mice) or the reporter gene (control RFP
mice) into the dorsal striatum of ChAT cre/cre mice. The AAV (1 !l) was
injected unilaterally at 2 dorsoventral sites in the dorsal striatum of
ChAT cre/cre mice ("1.0 mm AP, #1.5 mm ML, $3.4 and $3.0 mm DV;
stereotaxic mouse atlas of Paxinos and Franklin, 2001).
6-OHDA lesions. Mice received one unilateral injection (1.5 !l) of
6-hydroxydopamine hydrochloride (2.7 !g/!l diluted in 0.9% sterile
NaCl containing 0.2% ascorbic acid; Tocris Bioscience) or vehicle (0.9%
NaCl in 0.2% ascorbic acid) into the substantia nigra pars compacta
(SNc) at the following coordinates: $3.0 mm AP, #1.3 mm ML, $4.5
mm DV. 6-OHDA or vehicle injection was done on the side of the intra-
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striatal viral injection in the same surgical session. All experiments were
performed at least 2 weeks later and the extent of DA lesion was assessed
systematically by anti-tyrosine hydroxylase immunochemistry.
Optic fiber implantation. For optogenetic experiments, mice were im-
planted with optical fibers consisting of a zirconia ferrule with a 200 !m
diameter and 3.0-mm-long cleaved bare optic fibers (0.22 numerical
aperture; Doric Lenses). Fibers were implanted in the striatum ipsilateral
to the lesion side at the following coordinates: "1.0 mm AP, # 1.5 mm
ML, $2.8 mm DV.
Cannula implantation. For intrastriatal injections, mice were implanted
with guide cannula (cut 2.5 mm below pedestal, 26 gauge; Plastics One)
ipsilaterally to the lesioned side at the following coordinates:"1.0 mm AP,#
1.5 mm ML, $2.5 mm DV.
Optogenetic photoinhibition
Light was provided by a yellow laser (589 nm, 75.2 mW, continuous
stimulation; Combined Dual Wavelength DPSS Laser System, Laser-
glow). Optical-fiber light power was measured using a light sensor and
intensity calculated using the model based on direct measurements in
mammalian brain tissue for predicting irradiance values developed in
K. Deisseroth’s laboratory. Light intensity at 0.2 mm from fiber tip
was calculated to be 20 mW/mm 2 for yellow light (corresponding to
140 mW/mm 2 at the fiber tip). The duration of optogenetic photoin-
hibition was dependent on each behavioral testing period (from few
seconds to 5 min).
In vivo recordings in anesthetized mice
eNpHR-RFP mice were anesthetized with a mixture of ketamine and
xylazine (100 and 10 mg/kg, i.p., respectively, supplemented as needed by
intraperitonal injection during the course of the experiment) and fixed in
a stereotaxic head frame (Horsley-Clarke apparatus; Unimécanique).
Body temperature was monitored by a rectal thermometer and main-
tained at 36.5°C with a homeothermic blanket (Harvard Apparatus).
Single-unit activity of striatal cells was recorded extracellularly using
glass micropipettes (25–35 M%) filled with a 0.5 M sodium chloride
solution containing 1.5% neurobiotin (Vector Laboratories). Single neu-
ron action potentials were recorded using the active bridge mode of an
Axoclamp-2B amplifier (Molecular Devices), amplified, and filtered with
an AC/DC amplifier (DAM 50; World Precision Instruments). Data were
sampled online at a 10 kHz rate on a computer connected to a CED 1401
interface and analyzed offline using Spike 2 (Cambridge Electronic De-
sign). An optical fiber (core 200 !m, numerical aperture 0.22; Doric
Lenses) was secured 800 !m from the tip of the glass micropipette
using dental cement and this custom optoprobe was lowered in the stria-
tum ("1.0 mm AP, #1.5 mm ML according to Paxinos and Franklin,
2001). Yellow light was delivered ( power at the tip of optical fiber:
140 mW/mm 2) using a yellow DPSS Laser (589 nm, 75.2 mW; Changc-
hun New Industries Optoelectronics).
Drug treatment
Scopolamine hydrobromide (1.0 mg/kg) and L-DOPA methyl ester (3.0
mg/kg) combined with the peripheral DOPA decarboxylase inhibitor
benserazide hydrochloride (12 mg/kg), telenzepine dihydrochloride hy-
drate (0.3 or 3.0 mg/kg), and tropicamide (2.5 or 10 mg/kg) were dis-
solved with 0.9% sterile NaCl immediately before use. The drugs were
injected intraperitoneally at a volume of 10 ml/kg body weight, 30 min
before behavioral tests to cover the period of maximal drug effect (Aliane
et al., 2011; Francardo et al., 2011). All drugs were purchased from
Sigma-Aldrich. For intrastriatal injections, awake mice received unilat-
eral injections of telenzepine (0.75 !g or 7.5 !g) or tropicamide (0.1, 1.0
or 6.0 !g) diluted in a volume of 0.5 !l in 0.9% sterile NaCl. Local
injections were performed with stainless-steel injector needles (cut 3.2
mm below pedestal, 33 gauge; Plastics One) inserted through the guide
cannula previously implanted and fitted so that they protruded 0.7 mm
below into the dorsal striatum. The injectors were connected via a poly-
ethylene catheter to a 10 !l microsyringe fitted to a micropump. The flow
delivered by the pump was set at 0.25 !l/min. Local injections were
performed a few minutes before testing.
Behavioral tests
Pole test. To evaluate bradykinesia induced by 6-OHDA lesion, mice were
placed head-upward on the top of a vertical, rough-surfaced pole (50 cm
height, 1 cm diameter). Mice were trained to turn to orient downward
and descend the pole in two sessions on consecutive days before
6-OHDA lesion. The total time to descend the pole from the time that the
animal was placed on the pole until it reached the base of the pole was
monitored. Two trials were performed and the best descent time was
taken across the trials.
Cylinder test. Mice were placed into a Plexiglas cylinder (20 cm height,
9 cm diameter) to evaluate akinesia and motor asymmetry induced by
6-OHDA lesion. The forelimb asymmetry was assessed by scoring during
5 min weight-bearing contacts on the cylinder wall of the ipsilateral and
contralateral paw relative to the lesioned hemisphere, as well as move-
ments made by both paws. Mice failing to reach 10 contacts were ex-
cluded from the analyses. Data are expressed as a percentage of ipsilateral
and contralateral touches relative to the total number of touches.
Cross maze. To evaluate exploratory behavior and sensorimotor ne-
glect induced by 6-OHDA lesion, mice were placed into a cross maze
consisting of 4 identical arms (45 & 7 & 15 cm) at 90° to each other and
made with clear Plexiglas. The acquisition started with the mouse placed
in the middle facing one arm. The number of ipsilateral and contralateral
turns and the number of times the mouse went straight was monitored
for 5 min. Mice failing to reach 10 entries were excluded from the anal-
yses. Data are expressed as a percentage of ipsilateral, contralateral, and
straight arm exploration relative to the total number of arm explorations.
Amphetamine-induced rotations. Rotational asymmetry was assessed
using Plexiglas bowls (8 cm height, 9 cm diameter). During testing, mice
were video recorded and full turns were counted in the ipsilateral and
contralateral directions for 40 min after the injection of D-amphetamine
sulfate (5 mg/kg, i.p., dissolved in 0.9% NaCl at a volume of 10 ml/kg).
Data are expressed as percentage of ipsilateral rotations toward the side of
the lesion relative to the total number of rotations over the 40 min of
testing.
Open field. Mice were individually transferred from the home cage to
an open-field arena (50 & 50 cm with a 30 cm-high white plastic wall)
virtually divided into peripheral, intermediate, and central zones. The
test started by placing the animal in the center of the open field illumi-
nated by a dim light (5 Lux). Each mouse was allowed to explore the open
field for 30 min and its behavior was recorded by a video camera. The
distance traveled and the time spent in the different zones was analyzed
by a video-tracking software (Viewpoint Life Sciences). In this test, the
preferential exploration of the peripheral zone of the open field is con-
sidered an index of anxiety.
Experimental design
Optogenetic experiments. One week before surgery, 28 mice were tested in
the pole, cylinder, and cross maze behavioral tests during the same ses-
sion ( prelesion). After 6-OHDA lesion and eNpHR or reporter gene
(RFP) injection, mice were divided into two groups: control RFP
6-OHDA (n ' 14) and eNpHR-RFP 6-OHDA (n ' 14). After 2 weeks of
recovery from surgery, the same behavioral tests were conducted in the
two groups with and without optogenetic photoinhibition ( postlesion
ON and OFF) in a counterbalanced manner.
Pharmacological experiments. For systemic treatments, sham (n ' 5– 8
per group) and 6-OHDA (n ' 10 –14 per group) mice received scopol-
amine, L-DOPA, telenzepine, or tropicamide intraperitoneally. Each
group (sham and 6-OHDA) was divided into three different subgroups
receiving three injections of a given drug (vehicle, dose 1 and dose 2),
except for the scopolamine and L-DOPA groups, which received two
injections (vehicle, dose 1) in a different order of injection following a
Latin-square design over postlesion days 14 –22. Between postlesion days
25 and 45, each group (sham and 6-OHDA) received vehicle and telen-
zepine or tropicamide at the lowest efficient dose and were then tested
twice on D-amphetamine-induced circling with a 15 d washout period in
between.
For local treatments, sham (n ' 6 –7 per group) and 6-OHDA (n ' 9
per group) mice, treated either with telenzepine or tropicamide, were
divided into 3 different subgroups receiving 3 intrastriatal injections
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Figure 1. Optogenetic inhibition of striatal ChIs reduces motor dysfunction in DA-depleted mice. A, Top, Tyrosine hydroxylase immunolabeling in the SNc after unilateral 6-OHDA injection
showing near-complete loss of dopaminergic neurons compared with the nonlesioned side. Scale bar, 500 !m. Bottom, Enlargement of the indicated squares. Scale bar, 20 !m. B, Left: specific
expression of halorhodopsin (eNpHR-RFP) in ChIs in the dorsal striatum. Cx, Cortex; Cc, corpus callosum. Right, Coexpression of eNpHR-RFP- and ChAT-expressing neurons in eNpHR-RFP-injected
mice. Scale bars, 500 !m (left) and 50 !m (right). C, D, Top, Raw trace of two isolated units, identified as ChIs, inhibited by yellow light continuous stimulation applied for 15 s and for 3 min. Bottom,
Average of the firing rate over time for each unit. E, Total descent time in the pole test in control RFP (n ' 14) and eNpHR-RFP (n ' 14) mice. F, Postural (Figure legend continues.)
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(vehicle, dose 1, and dose 2) over postlesion days 14 –22. As for systemic
treatments, the order of local injections was designed using a Latin-
square design.
For D1-M4-KO experiments, 37 mice divided into control (M4
fl/fl, n ' 23) and D1-M4 KO (n ' 14) groups were tested. Before
6-OHDA lesion, control and D1-M4-KO mice were first tested in the
open field. After 2 weeks of recovery from surgery, each subgroup
(control sham, n ' 12; control 6-OHDA, n ' 11; D1-M4-KO sham,
n ' 6; D1-M4-KO 6-OHDA, n ' 8) received three intrastriatal injec-
tions (vehicle and tropicamide dose 1 and dose 2) in a different order
following a Latin-square design over postlesion days 14 –22.
All injections (systemic or intrastriatal) were performed once every 4 d
and mice were tested in the cylinder and cross maze tests consecutively in
the same session.
Histology, immunohistochemistry and microscopy
Opsin striatal expression and lesion verification. Animals were deeply anes-
thetized with pentobarbital (100 mg/kg) and then transcardially perfused
with an ice-cold solution of paraformaldehyde 4% in PBS. After dissec-
tion, brains were postfixed overnight in the same fixative at 4°C, cryo-
protected in 30% sucrose dissolved in 1& PBS for an additional 36 h at
4°C, and frozen. Coronal cryostat sections (40 !m) covering the antero-
posterior extent of the striatum were used for labeling. Brain sections
were permeabilized in PBS with 0.4% Triton X-100 (PBST) for 30 min at
room temperature. Sections were then incubated in a blocking solution
composed of PBST with 3% bovine serum albumin and 10% normal goat
serum for 1 h at room temperature. For primary antibody exposure,
brain sections were incubated overnight at 4°C in rabbit anti-RFP (1/
1000, tebu-bio, 600 – 401-379) and goat anti-ChAT (1/100, Millipore,
AB144P) for colocalization experiments and in mouse anti-tyrosine hy-
droxylase (1/1000, Millipore, MAB318, AB144P RRID:AB_2079751) to
control DA lesion. Sections were then incubated, respectively, in Alexa
Fluor 555 donkey anti-rabbit (1/500, Invitrogen, A31572; Thermo Fisher
Scientific, A-31572 RRID:AB_2536182), Alexa Fluor 488 donkey anti-
goat (1/500, Invitrogen, A11055; Thermo Fisher Scientific, A-11055
RRID:AB_2534102), and Alexa Fluor 555 donkey anti mouse (1/500,
Invitrogen, A31570; Thermo Fisher Scientific, A-31570 RRID:AB_25
36180) for 1 h and 30 min at room temperature. Immunostaining was
done on free-floating sections, which were then mounted onto Super-
Frost Plus glass slides (VWR) and coverslipped with FluorSave mounting
medium (Merck Chemicals). Quantification of colocalization was per-
formed from approximately bregma "1.42 to "0.02 mm ((14 sections
per mouse) using the Mercator System (Explora Nova) combined with a
DMR Leica microscope coupled to a DXC-990P color video camera
(Sony). Images were collected using Axio Imager Z1 with the Apotome
system (Zeiss) with a Plan-Apochromat 20&/0.8 or a Plan-Neofluar &40/
1.3 objective (Zeiss) for the high magnification or with a Plan-Apochromat
10&/0.45 objective to acquire whole-brain images.
Control of cannula and optic fiber implantation. Cresyl violet staining of
sections was used to locate the trace of cannula implantation and to
confirm the accuracy of injection sites and correct optic fiber placement.
Statistical analysis
All behavioral analyses were conducted on littermates and the values are
presented as mean # SEM. The effects of 6-OHDA lesion, optogenetic
photoinhibition, or pharmacological treatments on behavioral perfor-
mances of the different groups were tested by means of repeated-
measures one-way or two-way ANOVA, followed by adapted post hoc
tests between groups (Bonferroni’s or Tukey’s multiple-comparisons
test). For the locomotor activity (open field), data were analyzed using
unpaired Student’s t test. Values of p ) 0.05 were considered significant
for all analyses. Statistical analyses were performed using Prism 6 soft-
ware (GraphPad).
Results
Photoinhibition of striatal ChI activity alleviates
parkinsonian-like motor symptoms
We examined the impact of optogenetic photoinhibition of stri-
atal ChIs on motor function in parkinsonian conditions. Unilat-
eral 6-OHDA injection into the SNc resulted in a near-complete
loss of dopaminergic neurons compared with the nonlesioned
side (Fig. 1A). In eNpHR-RFP mice, opsin-expressing neurons
were largely confined to the dorsal part of the striatum and were
identified as ChAT-expressing neurons (Fig. 1B).
In vivo electrophysiological recordings of ChIs in anesthetized
nonlesioned eNpHR-RFP mice were performed to verify the impact
on their electrophysiological activity of eNpHR photostimulation
applied continuously for 15 s (Fig. 1C) and 3 min (Fig. 1D). Yellow
light inhibited action potential firing of striatal ChIs during the en-
tire duration of laser illumination in the two conditions.
To evaluate bradykinesia, mice were first tested in the pole
test. 6-OHDA mice, either control RFP or eNpHR-RFP, showed
a significant increase in the total time to descend the pole com-
pared with prelesion level [Fig. 1E; F(2,26) ' 4.534, p ' 0.0205,
Tukey’s test, p ' 0.0067 (control RFP); F(2,26) ' 4.553, p '
0.0202, Tukey’s test, p ' 0.0075 (eNpHR-RFP)]. Yellow laser
(589 nm) illumination of striatal ChIs ipsilateral to the lesioned
side did not affect the descent time of control RFP 6-OHDA mice
(Tukey’s test, laser ON versus OFF, p ' 0.3631), whereas it sig-
nificantly reduced the descent time of eNpHR-RFP 6-OHDA
mice (Tukey’s test, laser ON versus OFF, p ' 0.0394).
Unilateral 6-OHDA mice were then tested for forelimb asym-
metry using the cylinder test (Fig. 1F). Before lesion, either
control RFP or eNpHR-RFP mice used their two forepaws indif-
ferently during exploratory rearing. The score of forepaws use is
close to 50%, showing that nonlesioned mice have no preference
between left or right paw use. In contrast, control RFP and
eNpHR-RFP 6-OHDA mice significantly used their forepaw ip-
silateral to the lesion due to contralateral forelimb akinesia, com-
pared with prelesion [F(2,12) ' 37.21, p ) 0.0001, Tukey’s test,
p ) 0.0001 (control RFP); F(2,12) ' 24.92, p ) 0.0001, Tukey’s
test, p ) 0.0001 (eNpHR-RFP)]. Yellow laser illumination of
striatal ChIs showed no significant difference in control RFP
6-OHDA mice (Tukey’s test, laser ON versus OFF, p ' 0.2630),
whereas it produced a significant reduction of the ipsilateral
asymmetry in eNpHR-RFP 6-OHDA mice (Tukey’s test, laser
ON versus OFF, p ' 0.0211).
We further tested mice in a novel exploratory cross maze en-
vironment (Fig. 1G,H). Before 6-OHDA lesion, the natural ten-
dency of mice is to explore the apparatus mainly by going back
and forth into the straight arm (60% of the time in prelesion
condition), with only a few equivalent turns into the right or left
arms (20%). Unilateral 6-OHDA lesion in the control RFP and
eNpHR-RFP groups totally disrupted this strategy by inducing a
bias in arm explorations. We observed a significant increase of
ipsilateral turns to the lesioned side associated with a decrease of
contralateral turns and straight arm exploration, reflecting sen-
sorimotor neglect [Fig. 1G,H; F(8,104) ' 34.3, p ) 0.0001, Tukey’s
test, p ) 0.0001, p ' 0.0018, p ) 0.0001 ipsilateral, contralateral,
and straight arm exploration, respectively (control RFP);
F(8,104) ' 24.92, p ) 0.0001, Tukey’s test, p ) 0.0001, p ' 0.0312,
p ) 0.0001 ipsilateral, contralateral, and straight arm explora-
tion, respectively (eNpHR-RFP)]. Yellow laser illumination of
striatal ChIs did not affect exploration in control RFP 6-OHDA
4
(Figure legend continued.) asymmetry in the cylinder in control RFP (n ' 7) and eNpHR-RFP
(n ' 7) mice. G, H, Arm exploration (ipsilateral, contralateral, and straight arm exploration) in
the cross maze in control RFP (n ' 14) and eNpHR-RFP (n ' 14) mice. Behavioral tests were
performed under three conditions: prelesion, 6-OHDA laser OFF, and 6-OHDA laser ON. Data are
reported as mean # SEM. Tukey’s test after significant one-way repeated-measures ANOVA:
*p ) 0.05 versus prelesion condition; #p ) 0.05, laser ON versus laser OFF.
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mice (Fig. 1G; Tukey’s test, laser ON ver-
sus OFF, p ' 0.2636, p ' 0.6856, p '
0.4736 ipsilateral, contralateral, and
straight arm exploration, respectively),
whereas it significantly decreased ipsi-
lateral arm exploration and increased
straight arm exploration in eNpHR-RFP
6-OHDA mice. A tendency to enter the
contralateral arm was also observed, but
did not reach a significant level (Fig. 1H;
Tukey’s test, laser ON versus OFF, p '
0.0035, p ' 0.2874, p ' 0.0328 ipsilateral,
contralateral, and straight arm explora-
tion, respectively).
Muscarinic receptors blockade in
unilateral 6-OHDA mice restores
motor function
To investigate which cholinergic recep-
tors are involved in the anti-parkinsonian
effects, we tested the blockade of mAChRs
with scopolamine, a large-spectrum an-
tagonist. Unilateral 6-OHDA lesion
induced a significant increase of the ipsi-
lateral asymmetry in the cylinder test.
Scopolamine (1 mg/kg, i.p.) significantly
reduced the ipsilateral asymmetry of
6-OHDA mice in the cylinder but had no
significant effect in the sham group [Fig.
2A1; F(1,20) ' 103.7, p ) 0.0001, Bonfer-
roni’s test, p * 0.9999 (sham) and p )
0.0001 (6-OHDA)]. Scopolamine, at the
same dose of 1 mg/kg that did not modify
exploratory behavior of sham group in the
cross maze (Fig. 2A2; F(2,21) ' 1.206, p '
0.3192), significantly modified 6-OHDA
mice behavior (F(2,39) ' 73.99, p )
0.0001). It also decreased ipsilateral arm
exploration and increased straight arm
exploration, but did not affect contralat-
eral bias in 6-OHDA mice (Bonferroni’s
test, p ) 0.0001, p ' 0.8645, p ) 0.0001
ipsilateral, contralateral, and straight arm
exploration, respectively).
To compare the therapeutic effect of
L-DOPA in these assays, an acute injection
of L-DOPA was tested in separate groups of 6-OHDA mice.
L-DOPA at a dose of 6 mg/kg induced contralateral rotations and
forelimb abnormal involuntary movements (AIMs) in all tested
animals (n ' 6), defined as dyskinesia (data not shown), prevent-
ing behavioral assessment in the cylinder and cross maze tests.
L-DOPA injected at 3 mg/kg intraperitoneally in a group of 14
6-OHDA mice produced AIMs in 4 of them, so these mice were
excluded from the analysis. In the lesioned mice that did not show
dyskinesia, L-DOPA significantly reduced the ipsilateral asym-
metry in the cylinder [Fig. 2B1; F(1,15) ' 86.02, p ) 0.0001, Bon-
ferroni’s test, p * 0.9999 (sham) and p ) 0.0001 (6-OHDA)]. It
also decreased ipsilateral arm exploration and increased con-
tralateral and straight arm exploration in the cross maze of
6-OHDA mice (F(2,27) ' 110.3, p ) 0.0001; Bonferroni’s test, p )
0.0001, p ) 0.0001, p ' 0.0011 ipsilateral, contralateral, and
straight arm exploration, respectively) but had no effect on the
exploratory behavior of sham group (Fig. 2B2; F(2,18) ' 1.059,
p ' 0.3676).
M1 and M4 mAChRs blockade improves motor functions in
unilateral 6-OHDA mice
To determine which muscarinic receptors are involved in these
effects, we injected selective M1 and M4 mAChR antagonists
(telenzepine and tropicamide, respectively). In this study, doses
of mAChR antagonists were selected because of their lack of effect
on spontaneous locomotion in nonlesioned animals (data not
shown).
The preferential M1 mAChR antagonist telenzepine (0.3 and 3
mg/kg, i.p.) dose-dependently reduced the ipsilateral asymmetry in
6-OHDA mice in the cylinder but had no significant effect in the
sham group [Fig. 3A1; F(2,26) ' 8.897, p ' 0.0011; Tukey’s test, p '
0.9908 (0.3 mg/kg) and p ' 0.9997 (3 mg/kg) for sham; p ' 0.0477
(0.3 mg/kg) and p ) 0.0001 (3 mg/kg) for 6-OHDA]. Telenzepine
Figure 2. Muscarinic receptor blockade and L-DOPA administration restore motor function in DA-depleted mice. A, Effects of the
nonselective mAChR antagonist scopolamine (1 mg/kg, i.p.) in the cylinder (A1) and cross maze (A2) tests. Each sham (n ' 8) and
6-OHDA (n ' 14) group received 2 injections (vehicle or scopolamine, 1 mg/kg). Values are shown as mean # SEM. Bonferroni’s
test after significant two-way repeated-measures ANOVA: *p ) 0.01 versus vehicle-sham group; #p ) 0.01 versus vehicle-6-
OHDA group. B, Effects of L-DOPA (3 mg/kg, i.p.) in the cylinder (B1) and cross maze (B2) tests. Each sham (n ' 7) and 6-OHDA
(n ' 10) group received 2 injections (vehicle or L-DOPA 3 mg/kg). Values are shown as mean # SEM. Bonferroni’s test after
significant two-way repeated-measures ANOVA: *p ) 0.01 versus vehicle-sham group; #p ) 0.01 versus vehicle-6-OHDA group.
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had no effect on the sham group in the cross
maze [Fig. 3A2; F(4,24) ' 1.540, p ' 0.2224],
but significantly decreased ipsilateral bias
and increased straight arm exploration in
6-OHDA mice [F(4,54) ' 17.11, p ) 0.0001;
Tukey’s test, p ' 0,0036 (0.3 mg/kg) and
p ) 0,0001 (3 mg/kg) for ipsilateral; p '
0.5735 (0.3 mg/kg) and p ' 0.1641 (3 mg/
kg) for contralateral; p'0.0533 (0.3 mg/kg)
and p ) 0.0001 (3 mg/kg) for straight arm
exploration]. The effects of M1 mAChR
blockade were then tested on amphet-
amine-induced rotational asymmetry.
Amphetamine (5 mg/kg, i.p.) induced ipsi-
lateral rotations in 6-OHDA mice. Telenz-
epine at a dose of 0.3 mg/kg reduced
amphetamine-induced rotations over the
40 min test in 6-OHDA mice but had no
effect in sham group [Fig. 3A3; F(1,12) '
6.636, p ' 0.0243, Bonferroni’s test, p *
0.9999 (sham) and p ' 0.0023 (6-OHDA)].
In 6-OHDA mice, the preferential M4
mAChR antagonist tropicamide (2.5 and
10 mg/kg, i.p.) dose-dependently reduced
the ipsilateral asymmetry in 6-OHDA
mice in the cylinder but had no significant
effect in sham group [Fig. 3B1; F(2,26) '
7.560, p ' 0.0026; Tukey’s test, p ' 0.9007
(2.5 mg/kg) and p ' 0.9335 (10 mg/kg)
for sham; p ) 0.0001 (2.5 mg/kg) and p )
0.0001 (10 mg/kg) for 6-OHDA]. Tropic-
amide had no effect on the sham group in
the cross maze (Fig. 3B2; F(4,24) ' 1.002,
p ' 0.4257], whereas it significantly de-
creased ipsilateral arm exploration and
increased straight arm exploration in
6-OHDA mice [F(4,54) ' 12.38, p )
0.0001; Tukey’s test, p ' 0,0052 (2.5 mg/
kg) and p ) 0,0001 (10 mg/kg) for ipsilat-
eral; p ' 0.7976 (2.5 mg/kg) and p '
0.9690 (10 mg/kg) for contralateral; p '
0.0292 (2.5 mg/kg) and p ) 0.0001 (10
mg/kg) for straight arm exploration]. In
amphetamine-induced rotational asym-
metry, ipsilateral rotations produced by
6-OHDA lesion were reduced by tropic-
amide at the dose of 2.5 mg/kg, whereas
no such effect was observed in the sham
group [Fig. 3B3; F(1,12) ' 5.026, p '
0.0446, Bonferroni’s test, p * 0.9999
(sham) and p ' 0.0067 (6-OHDA)].
Dorsal striatal M1 and M4 mAChR
blockade is involved in the beneficial
effect on parkinsonian-like motor
deficits
To investigate the role of M1 and M4
mAChRs of the striatum in the mediation
of these behavioral effects, we injected
telenzepine or tropicamide directly into
the dorsal part of the striatum (Fig. 4A).
Only mice showing the appropriate injec-
tion sites were used for data analysis. In-
Figure 3. M1 and M4 mAChR blockade improves motor function in DA-depleted mice. A, Effects of the selective M1
mAChR antagonist telenzepine (0.3 and 3 mg/kg, i.p.) in the cylinder (A1) and cross maze (A2) tests. Each sham (n ' 5) and
6-OHDA (n ' 10) group received 3 injections (vehicle or telenzepine 0.3 and 3 mg/kg). Data are reported as mean # SEM.
Tukey’s test after significant two-way repeated-measures ANOVA: *p ) 0.01 versus vehicle-sham group; #p ) 0.05 versus
vehicle-6-OHDA group. Amphetamine-induced rotational asymmetry (A3) was further tested in each sham (n ' 5) and
6-OHDA (n ' 8) group, which received 2 injections (vehicle or telenzepine 0.3 mg/kg) with a 15 d washout period in
between. Values are shown as mean # SEM. Bonferroni’s test after significant two-way repeated-measures ANOVA: *p )
0.01 versus vehicle-sham group; #p ) 0.01 versus vehicle-6-OHDA group. B, Effects of selective M4 mAChR antagonist
tropicamide (2.5 and 10 mg/kg, i.p.) in the cylinder (B1) and the cross maze (B2). Each sham (n ' 5) and 6-OHDA (n ' 10)
group received 3 injections (vehicle or tropicamide 2.5 and 10 mg/kg). Data are reported as mean # SEM. Tukey’s test after
significant two-way repeated-measures ANOVA: *p ) 0.01 versus vehicle-sham group; #p ) 0.05 versus vehicle-6-OHDA
group. Amphetamine-induced rotational asymmetry (B3) was further tested in each sham (n ' 5) and 6-OHDA (n ' 8)
group, which received 2 injections (vehicle or tropicamide 2.5 mg/kg). Values are shown as mean # SEM. Bonferroni’s test
after significant two-way repeated-measures ANOVA: *p ) 0.01 versus vehicle-sham group; #p ) 0.01 versus vehicle-6-
OHDA group.
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trastriatal injection of telenzepine (0.75
and 7.5 !g) dose-dependently reduced
the ipsilateral asymmetry in the cylinder
(Fig. 4B1; F(2,28) ' 44.19, p ) 0.0001;
Tukey’s test, p ' 0.9783 (0.75 !g) and p '
0.9926 (7.5 !g) for sham; p ) 0.0001 (0.75
!g) and p ) 0.0001 (7.5 !g) for
6-OHDA]. Telenzepine had no effect on
sham group in the cross maze (Fig. 4B2;
F(4,36) ' 2.528, p ' 0.0574), whereas it
significantly decreased ipsilateral arm ex-
ploration and increased straight arm ex-
ploration in 6-OHDA mice [F(4,48) '
24.75, p ) 0.0001; Tukey’s test, p ) 0.0001
(0.75 !g) and p ) 0,0001 (7.5 !g) for ip-
silateral; p ' 0.8730 (0.75 !g) and p '
0.5503 (7.5 !g) for contralateral; p )
0.0001 (0.75 !g) and p ) 0.0001 (7.5 !g)
for straight arm exploration].
Local striatal injection of tropicamide
(1 and 6 !g) reduced ipsilateral asymme-
try significantly in the cylinder in a
dose-dependent manner [Fig. 4C1;
F(2,26) ' 13.14, p ' 0.0001; Tukey’s test,
p ' 0.9686 (1 !g) and p ' 0.8445 (6 !g)
for sham; p ' 0.0024 (1 !g) and p )
0.0001 (6 !g) for 6-OHDA]. Tropicamide
had no effect on the sham group in the
cross maze (Fig. 4C2; F(4,30) ' 2.484, p '
0.0648, whereas it significantly reduced
ipsilateral arm exploration and increased
straight exploration in 6-OHDA mice
[F(4,48) ' 31.47, p ) 0.0001; Tukey’s test,
p ' 0.0002 (1 !g) and p ) 0,0001 (6 !g)
for ipsilateral; p ' 0.2470 (1 !g) and p '
0.4087 (6 !g) for contralateral; p ' 0.0500
(1 !g) and p ) 0.0001 (6 !g) for straight
arm exploration)].
Local injection of M4 mAChR
antagonist has no effect on motor
deficits induced by unilateral 6-OHDA
lesion in transgenic D1-M4-KO mice
The effects of M4 mAChR deletion only
in D1-receptor-expressing neurons were
first evaluated on basal locomotor activity
in an open field for 30 min by comparing
nonlesioned D1-M4-KO mice and their
control littermates (M4 fl/fl mice) (Fig.
5A). The unpaired t test revealed a trend
toward increased global locomotion in
D1-M4-KO mice compared with control
mice that did not reach a significant level
(Fig. 5A; unpaired Student’s t test, t(19) '
1.379, p ' 0.1839). The exploratory be-
havior was evaluated by the time spent in
the peripheral, intermediate, and central
zones. D1-M4-KO mice spent significantly more time in the cen-
tral zone than did control mice (Fig. 5A; unpaired Student’s t test,
t(19) ' 2.151, p ' 0.0445), suggesting an anxiolytic phenotype in
these transgenic mice.
In control littermates, local striatal injection of tropicamide at
the dose of 1 !g reduced significantly the ipsilateral asymmetry in
the cylinder (Fig. 5B1; F(2,42) ' 27.38, p ) 0.0001; Tukey’s test,
p ' 0.9810 (0.1 !g) and p ' 0.9834 (1 !g) for sham; p ' 0.2386
(0.1 !g) and p ) 0.0001 (1 !g) for 6-OHDA]. Tropicamide had
no effect on the sham group in the cross maze (Fig. 5B2; F(4,66) '
2.379, p ' 0.0605). At the dose of 1 !g, tropicamide significantly
decreased ipsilateral arm exploration and increased straight ex-
Figure 4. Dorsal striatal M1 and M4 mAChR blockade alleviates parkinsonian-like motor deficits. A, Schematic coronal sections
from the stereotaxic mouse atlas (Paxinos and Franklin, 2001) (left) and cresyl violet staining (right) at different anteriority levels
(from "1.10 to "0.86 mm related to bregma) showing the trace of cannula implantation and injector needle placement in the
dorsal striatum for M1 and M4 mAChR antagonist injections. Scale bar, 1 mm. B, Effects of intrastriatal injection of telenzepine
(0.75 and 7.5 !g, i.s.) in the cylinder (B1) and cross maze (B2) tests. Each sham (n ' 7) and 6-OHDA (n ' 9) group received 3
injections (vehicle or telenzepine 0.75 and 7.5 !g). Data are reported as mean # SEM. Tukey’s test after significant two-way
repeated-measures ANOVA: *p ) 0.01 versus vehicle-sham group; #p ) 0.01 versus vehicle-6-OHDA. C, Effects of intrastriatal
injection of tropicamide (1 and 6 !g, i.s.) in the cylinder (C1) and cross maze (C2) tests. Each sham (n ' 6) and 6-OHDA (n ' 9)
group received 3 injections (vehicle or tropicamide 1 and 6 !g). Data are reported as mean # SEM. Tukey’s test after significant
two-way repeated-measures ANOVA: *p ) 0.01 versus vehicle-sham group; #p ) 0.05 versus vehicle-6-OHDA.
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ploration in 6-OHDA mice [F(4,60) '
17.68, p ) 0.0001; Tukey’s test, p ' 0.7793
(0.1 !g) and p ) 0,0001 (1 !g) for ipsilat-
eral; p ' 0.9366 (0.1 !g) and p ' 0.2258
(1 !g) for contralateral; p ' 0.5689 (0.1
!g) and p ) 0.0001 (1 !g) for straight arm
exploration)].
Interestingly, tropicamide at the same
dose did not reverse the 6-OHDA-
induced ipsilateral asymmetry of D1-
M4-KO mice (Fig. 5C1; F(2,24) ' 0.2069,
p ' 0.8146). In the cross maze, tropic-
amide had no effect on the sham group
(Fig. 5C2; F(4,30) ' 1.070, p ' 0.3888) and
did not reverse the 6-OHDA-induced
sensorimotor neglect in D1-M4-KO mice
(Fig. 4C2; F(4,42) ' 2.315, p ' 0.0730).
Comparisons across D1-M4-KO mice
and control littermates showed a main
significant interaction between groups
and treatment in the cylinder (Fig. 5B1–
C1; F(6,66) ' 14.78, p ) 0.0001) and the
cross maze (Fig. 5B2–C2; F(10,102) ' 3.822,
p ' 0.0002). Tropicamide at a dose of 1 !g
significantly affected ipsilateral bias be-
tween 6-OHDA control and 6-OHDA
D1-M4-KO mice in the cylinder (Fig.
5B1–C1; Tukey’s test, p ' 0.0012) and the
cross maze (Fig. 5B2–C2; Tukey’s test, p '
0.0225 for ipsilateral arm exploration).
Discussion
Although our understanding of the contri-
bution of the striatal ChI to basal ganglia-
related motor and cognitive functions is
growing (Aosaki et al., 2010; Straub et al.,
2014), many questions remain unanswered
regarding their involvement in the patho-
physiology of Parkinson’s disease. Here, we
show that the selective photoinhibition of
striatal ChIs and systemic administration or
intrastriatal pharmacological blockade of ei-
ther M1 or M4 mAChRs in the dorsal stria-
tum alleviate sensorimotor deficits in a
unilateral 6-OHDA mice model of Parkin-
son’s disease. We further demonstrate that
the beneficial effect of M4 antagonism is lost
in mice lacking M4 mAChRs selectively in
D1-MSNs. These data provide strong evi-
dence that dysregulated striatal cholinergic
transmission via M1/M4 mAChRs, in par-
ticular M4 receptors expressed by D1-
MSNs, is central in motor symptomatology,
suggesting promising targets for the devel-
opment of anti-parkinsonian strategies.
An imbalance between the DA and ACh
systems in the dorsal and ventral striatum
has long been implicated in the regulation of
movement disorders (Pisani et al., 2007; Ao-
saki et al., 2010; Lester et al., 2010). Selective
ventral striatal cholinergic depletion with
immunotoxin-mediated cell-targeting
techniques results in marked locomotor re-
Figure 5. Suppression of the beneficial effect of tropicamide on parkinsonian-like motor deficits in transgenic mice
lacking M4 mAChRs only in D1-receptor-expressing neurons. A, Effects of selective M4 mAChRs deletion only in D1-
receptor-expressing neurons (D1-M4-KO) on basal locomotor activity (30 min) in nonlesioned mice. Representative paths
and exploratory behavior of D1-M4-KO mice (n ' 8) compared with their control littermates M4 fl/fl (n ' 13). Quantifi-
cation showing global locomotion and the time spent in the central zone of the open field. Values are shown as mean #
SEM. Unpaired Student’s t test: *p ) 0.05. B, Effects of intrastriatal injection of tropicamide (0.1 and 1 !g, i.s.) in the
cylinder (B1) and cross maze (B2) tests in control littermates. Each sham (n ' 12) and 6-OHDA (n ' 11) group received 3
injections (vehicle or tropicamide 0.1 and 1 !g). Data are reported as mean # SEM. Tukey’s test after significant two-way
repeated-measures ANOVA: *p ) 0.01 versus vehicle-sham group; #p ) 0.01 versus vehicle-6-OHDA; ¤p ) 0.05 versus
tropicamide 1 !g-6-OHDA D1-M4-KO mice. C, Effects of intrastriatal injection of tropicamide (0.1 and 1 !g, i.s.) in the
cylinder (C1) and cross maze (C2) test in D1-M4-KO mice. Each sham (n ' 6) and 6-OHDA (n ' 8) group received 3
injections (vehicle or tropicamide 0.1 and 1 !g). Data are reported as mean # SEM. Tukey’s test after significant two-way
repeated-measures ANOVA: *p ) 0.01 versus vehicle-sham group.
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sponse to DA stimulation and disruption of sensorimotor-gating
processes (Hikida et al., 2001; Laplante et al., 2011). In the dorsal
striatum, unilateral immunotoxin-mediated cholinergic depletion
produces abnormal contralateral turning behavior that is enhanced
by apomorphine (Kaneko et al., 2000). Moreover, viral-targeted ab-
lation of ChIs of the dorsolateral, but not dorsomedial, striatum
induces robust stress- and amphetamine-induced stereotyped be-
havior related to Tourette symptoms (Xu et al., 2015). Interestingly,
unlike viral-targeted ablation, the optogenetic photoinhibition of
striatal ChIs in control conditions does not modify spontaneous
locomotion nor substantia nigra reticulata electrophysiological ac-
tivity (Maurice et al., 2015).
The validity of optogenetic tools was assessed by recording
ChI firing activity in anesthetized eNpHR-RFP mice, which con-
firmed the inhibition of ChI action potential firing under eNpHR
photoillumination. The reversal of motor improvement is there-
fore directly linked to the reduction of striatal cholinergic tone in
DA-depleted animals and its consequences on MSN membrane
excitability, synaptic connectivity, and dendritic morphological
changes (Surmeier et al., 2014; Maurice et al., 2015). Recent
studies, however, have questioned the antagonistic nature of
DA–ACh interaction. Synchronous activation of ChIs was found
to elevate striatal DA release via nicotinic receptor activation
(Threlfell and Cragg, 2011; Cachope et al., 2012; Threlfell et al.,
2012). In addition, stimulation of muscarinic receptors may ei-
ther reduce or enhance striatal DA release depending on the stud-
ies, suggesting that these interactions are more complex than was
originally thought (Eskow Jaunarajs et al., 2015).
Nonselective mAChR antagonists were the first pharmacolog-
ical treatment for Parkinson’s disease and are still used for tremor
and gait symptoms. In the present study, we first show that ChIs
photoinhibition effect is reproduced by systemic administration
of scopolamine, a nonselective mAChRs antagonist. This is con-
sistent with improved motor symptoms of parkinsonian patients
treated with benztropine (Duvoisin, 1967) and in recent animal
studies (Ding et al., 2011; Xiang et al., 2012). However, their
clinical utility has been seriously limited by systemic and central
adverse effects caused by nonselective blockade of multiple
mAChRs also located in limbic structures. The recent discovery
of drugs that act selectively at the M1 or M4 mAChR subtypes
may provide new tools to treat motor symptoms with fewer side
effects (Langmead et al., 2008; Lester et al., 2010). In addition, M4
receptors are primarily expressed in the striatum and, at lower
levels, in several other brain regions, including cerebral cortex
and hippocampus (Gomeza et al., 1999). This may prevent the
occurrence of cognitive side effects.
Immunocytochemical studies reveal a predominant expres-
sion of M1 and M4 mAChRs, relative to M2 and M3 subtypes,
within the striatum (Bonsi et al., 2011). M1 mAChRs are coupled
to Gq proteins that activate phospholipase C, resulting in activa-
tion of inositol trisphosphatase and diacyl-glycerol, ultimately
increasing intracellular calcium (Pisani et al., 2007). Striatal M1
mAChRs are highly expressed postsynaptically in both D1-MSNs
and D2-MSNs. Their blockade is thus expected to inhibit the
activity of the two output pathways. Here, we demonstrate that
the M1 preferential antagonist telenzepine, administered system-
ically or locally in the dorsolateral striatum, reduces 6-OHDA-
induced motor deficits as observed after scopolamine treatment
or striatal ChI photoinhibition. Telenzepine is reported to have
preferential activity at M1 mAChRs compared with other mus-
carinic subtypes (Doods et al., 1987) and is four to 10 times more
potent than pirenzepine, a widely used M1 mAChR antagonist
(Eltze et al., 1985). Interestingly, pirenzepine was also found to
inhibit haloperidol-induced catalepsy in rats when centrally in-
jected and was more effective than M2, M3, or M4 antagonists
(Erosa-Rivero et al., 2014), supporting the importance of M1
mAChR subtypes as an interesting anti-parkinsonian drug target.
In vitro electrophysiological studies revealed that ACh has been
involved in striatal long-term potentiation (LTP) or long-term
depression (LTD) induction. An excessive cholinergic transmis-
sion overactivates M1 mAChRs, thus preventing LTD in favor of
LTP (Bonsi et al., 2008). Cholinergic receptor antagonists (piren-
zepine, trihexyphenidyl) were able to restore a normal expression
of LTD. Because the indirect pathway is considered hyperactive
in parkinsonian state, whereas the direct pathway is hypoactive,
it may be postulated that the beneficial action of telenzepine
reported here involves preferential blockade of M1 mAChRs
located on D2-MSNs.
Whereas actions of M1 mAChRs have been explored exten-
sively, much less is known about M4 mAChRs that are highly
expressed in the striatum (Langmead et al., 2008; Chapman et al.,
2011). Consistent with the beneficial action of M4 mAChR block-
ade measured on sensorimotor deficits, tropicamide has been
reported to suppress tremulous jaw movements in a rodent
model of parkinsonian tremor (Betz et al., 2007). Moreover, sco-
polamine reversed haloperidol-induced catalepsy in wild-type
mice, but had only a weak effect in M4 knock-out mice, thus
highlighting a predominant role of these receptors in these effects
(Karasawa et al., 2003). M4 mAChRs activate Gi/o proteins and
are located in the striatum presynaptically on striatal ChI termi-
nals, where they function as cholinergic autoreceptors inhibiting
ACh release, along with M2 mAChRs (Kreitzer, 2009), and post-
synaptically on D1-MSNs, where their activation results, among
other mechanisms, in Cav2 channel inhibition and therefore
shapes the spiking of MSNs (Santiago and Potter, 2001; Pisani et
al., 2007). The loss of striatal DA has been reported to attenuate
M4 autoreceptor signaling in ChIs, which might be a main factor
in elevated striatal ACh release after DA depletion (Ding et al.,
2006). Such adaptation is likely to limit the outcomes of M4
autoreceptor antagonism, which should otherwise have pro-
parkinsonian rather than anti-parkinsonian action. After DA de-
pletion, tropicamide may thus act preferentially on postsynaptic
M4 receptors expressed in D1-MSNs, accounting for the symp-
tomatic relief found there. We validated our hypothesis by
showing that the alleviation of motor deficits by tropicamide is
lost in mutant mice that lack M4 mAChRs in D1 DA-receptor-
expressing cells (Jeon et al., 2010). These data indicate that acti-
vation of M4 mAChRs in D1-MSNs is a key component of ChIs
involvement in parkinsonian symptomatology and are consistent
with our recent work showing predominant outcomes of ChI
inhibition on D1-MSNs versus D2-MSNs in 6-OHDA-lesioned
mice, both in terms of excitability and implication in cortical
information processing through the basal ganglia (Maurice et al.,
2015). M4 mAChR subtypes exert an inhibitory control on D1-
receptor-mediated locomotor stimulation (Gomeza et al., 1999).
Their stimulation potently counteracts the activation of adenylyl
cyclase induced by a selective D1 receptor agonist in membranes
of the ventral striatum, strongly suggesting that the DA–ACh
balance takes place in D1-MSNs (Onali and Olianas, 2002). Here,
D1-M4-KO mice exhibit enhanced basal locomotor activity and
anxiolytic phenotype consistent with an increase of DA efflux in
the ventral striatum associated with an hyperlocomotor response
to psychostimulants observed previously in these mutant mice
(Jeon et al., 2010; Dencker et al., 2011). One could expect reduced
sensorimotor symptoms in D1-M4-KO mice if similar adaptive
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mechanisms occur in the dorsal striatum, but not in our condi-
tions of severe dopamine denervation.
The complexity of D1 and M4 mAChR interactions in the
treatment of L-DOPA-induced dyskinesia (LIDs) has also been
highlighted recently. In vitro, the actions of the M4 and D1 recep-
tors may be additive to produce a robust enhancement of
D1-MSN excitability or, conversely, oppose each other depend-
ing on the order of their activation (Hernández-Flores et al.,
2015). Such an antagonistic interaction of M4 and D1 receptors
may explain a recent work showing that increasing cholinergic
signaling with an M4 mAChR-positive allosteric modulator at-
tenuates LIDs by promoting D1-MSN LTD in mice (Shen et al.,
2015). In contrast, selective ablation of striatal ChI or mAChR
blockade reduces LIDs (Ding et al., 2011; Won et al., 2014; Bordia
et al., 2016), supporting the hypothesis that blockade rather than
enhancement of cholinergic activity at M4 mAChRs may be rel-
evant to alleviating LIDs and parkinsonian motor symptoms.
In the present study, administration of either muscarinic an-
tagonists or L-DOPA alleviated sensorimotor deficits in unilateral
6-OHDA-lesioned mice. However, L-DOPA also produces con-
tralateral bias and sometimes dyskinesia, which may indicate the
limits of L-DOPA treatment for restoring normal function in our
model of extensive dopamine denervation.
In summary, striatal ChI photoinhibition and M1 or M4
mAChR blockade alleviate parkinsonian-like motor symptoms
in 6-OHDA-lesioned mice. M1 mAChR blockade may act pref-
erentially on the indirect pathway, whereas M4 mAChR blockade
involves the direct pathway. Therefore, the development of com-
bined M1/M4 mAChR blockers appears to be a particularly at-
tractive goal for reducing striatal cholinergic tone to alleviate
the motor symptoms of Parkinson’s disease while limiting side
effects.
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